Policy and Issuance Patient Age Group: ( ) N/A ( ) All Ages ( ) Newborns ( X) Pediatric ( X) Adult
|
|
- Jessie Morgan
- 5 years ago
- Views:
Transcription
1 Applies To: Ambulatory Services Responsible Department: Ambulatory Admin Revised: 02/2018 Title: Controlled Substance Prescription Processing, Security Policy and Issuance Patient Age Group: ( ) N/A ( ) All Ages ( ) Newborns ( X) Pediatric ( X) Adult POLICY STATEMENT The purpose of this policy is to set forth standards for the processing, security and issuance of schedule I through V controlled substance prescriptions in the ambulatory setting. UNMH ensures secure handling and storage of all controlled substance prescriptions. All controlled substance prescriptions written in the ambulatory setting and not given directly to the patient at the time of visit shall be secured. Said prescriptions shall be issued only by authorized personnel and with proper authorization and identification of the person picking up the prescription. APPLICABILITY All UNM Hospital Clinics POLICY AUTHORITY Hospitals CEO s, Administrator, Ambulatory Services REFERENCES New Mexico Board of Pharmacy (BOP), (2014) [ NMAC - Rp 16 NMAC 19.20(1), ; A, ] New Mexico Medical Board, NMAC-N,1120/03;A,4/3/05, A,11/30/16. AREAS OF RESPONSIBILITY 1. The Medical Director and Unit Director are responsible for oversight of the adherence to the policy by all parties involved. 2. For patients age 14 years and older receiving controlled substances for pain management greater than 4 days the process shall be the same as for adults. a. PMP's will be reviewed every 3 months for patients 14 years of age and older on stimulant therapy for ADHD. Controlled substance agreements and urine drug screens are not required. b. Pediatric patients, regardless of age, on controlled substances for chronic conditions such as spasticity or seizures will have PMP reviewed every 3 months. Controlled substance agreements and urine drug screens are not required. 3. The prescribing provider is responsible for completing the Controlled Medicine Agreement on all patients receiving opioids for chronic pain for a period of 3 months or longer. The Controlled Medicine Agreement should be updated if medication is changed, additional medications are added, initiating provider changes or as deemed necessary by the clinician. Clinicians are encouraged to use the Controlled Medicine Agreement for other high risk medications such as benzodiazepines and stimulants. 4. The clinician will enter in the medication profile and in the problem list that the patient is on a Controlled Medicine Agreement. Page 1 of 9
2 5. The Controlled Medicine Agreement will be copied for the controlled substance folder and the original sent to scanning under Urgent Clinical documents utilizing the appropriate HIM cover sheet. 6. Patients on Controlled Medicine Agreements will have a Prescription Monitoring Program (PMP) checked at least every 3 months. 7. Clinicians are solely responsible for reviewing the PMP and must document their review of the report in the patient s Health Maintenance Module. 8. The clinician may designate printing of PMP to another staff person, according to the rules set forth by the Board of Pharmacy for assignment of proxy. 9. Clinicians shall review the PMP for the preceding 12 months before prescribing controlled substances for a period of greater than 4 days, or if there is a gap in prescribing for 30 days or more. 10. When available, clinicians shall review PMP reports for other states. 11. Upon review of a PMP report for a patient, the clinician shall identify, document and be aware of a patient currently receiving: a. opioids from multiple prescribers; b. opioids and benzodiazepines concurrently; c. opioids for more than 12 consecutive weeks; d. more than one controlled substance analgesic; e. opioids totaling more than 90 morphine milligram equivalents per day; or f. exhibiting potential for abuse or misuse of opioids and other controlled substances, such as overutilization, requests to fill early, requests for specific opioids, requests to pay cash when insurance is available, receiving opioids from multiple pharmacies. 12. A clinician does not have to obtain and review a PMP report before prescribing, ordering, or dispensing a controlled substance in schedule II, III, IV or V: a. for a period of four days or less; or b. to a patient in a nursing facility; or c. to a patient in hospice care; or d. when prescribing, dispensing or administering of: I. testosterone; or II. pregabalin; or lacosamide; or ezogabine; or III. stimulant therapy for pediatric patients less than age 14. (DO and Advanced RN practitioners cannot exclude these medications per their Title 16 Regulations) 13. A urine drug screen (UDM) will be obtained and reviewed by the prescribing clinician at the time of the initiation of an opioid and at least every 6 months while on therapy or sooner as deemed appropriate by the clinical circumstances and by the prescribing clinician. Clinicians are encouraged to utilize urine drug screens for other high risk medications such as benzodiazepines and stimulants at least every 6 months. Staff should obtain a urine drug screen a minimum of 6 months for all patients on a Controlled Medicine Agreement. 14. A patient who cannot void due to a medical condition or refuse to void, consider serum toxicology as an option. Page 2 of 9
3 15. If clinic utilizes the Controlled Substance Folder, it will contain at a minimum the current Controlled Medicine Agreement, Controlled Substance Prescription sign-out log, and a copy of patient s identification. Include proxy designee authorization form and identification of proxy (if applicable). 16. Retain controlled substance patient sign out log in for current and prior year, all other logs may be disposed of per current Records Management Retention and Disposal Policy. 17. The Unit Director or his/her designee is responsible for assisting in the resolution of problems which occur in the enforcement of the policy and for any needed exceptions, in conjunction with the attending physician. Attending physicians are responsible for education and oversight of the residents and fellows in completion of their responsibilities regarding controlled substance prescriptions. 18. If controlled substances are discontinued, the clinician is responsible for documenting rationale for this decision in the EHR and communicating the plan with the patient. Discontinuation of controlled substance agreement signed notation removed from Problem List, Controlled Substance Agreement removed from Medication List, and communication to staff for breakdown of folder. An additional option, Controlled Substance Agreement Terminated can be added to the Problem List. 19. Designated clinic staff is responsible for ensuring the patient or designee is given the controlled substance prescriptions according to the distribution schedule. When writing more than one prescription for future fill dates each prescription shall indicate a specific start date. 20. Designated clinic staff is responsible for establishing a working system to assure the patient s prescription needs are communicated to the clinicians and teams in a timely manner. 21. Clinicians are responsible for refilling controlled prescriptions at least 5 business days prior to next start date, unless the patient has an upcoming appointment and can get the prescription at the visit. 22. Clinicians can write for and/or release to patient up to 3 months of prescriptions with appropriate start date if medically indicated. 23. Patients on a Controlled Medication Agreement should be scheduled for reevaluation of pain and course of treatment at least every 6 months. Advanced RN practitioners should see the patient for reevaluation every 3 months per their Title 16 regulations. 24. The clinic staff is responsible for assisting in the management of the controlled substance prescriptions system. This activity includes: a. Reviewing of Controlled Substance Folders; b. Verifying accuracy of controlled substance prescriptions; c. Assisting in the maintenance of controlled substance records. d. Noting next PCP appointment on sign out log and assisting with scheduling if not seen at least every 6 months e. Securing of the Controlled Substance Folder in a locked cabinet until the prescription is picked up by the patient or authorized designee. 25. The designated staff member issuing the prescription to the patient or designee is responsible for: a. Assuring the patient or designee has the correct identification, documenting verification ; b. Issuing the prescription to patient or authorized designee; Page 3 of 9
4 c. Documenting sign out date and patient or designee signature on the sign out log. IMPLEMENTATION PROCEDURES 1. Who may pick up controlled substance prescriptions? a. Patients receiving controlled substance prescriptions are encouraged to pick up the prescriptions themselves however, the patient may designate up to 3 separate persons who may also pick up the prescriptions, using the Controlled Medicine Prescription Pick-up Designee Form (attachment A). The designee must be prearranged in writing by the patient. The form will be offered to the patient at the time the Controlled Medicine Agreement is signed and/or prescription written. The patient and/or designee must present a government issued or other photo ID in order to pick up the prescription. b. Patients who are in the post-operative period often need assistance picking up their prescriptions. If this is the case, both the patient s ID as well as the designee s will be required for issuance. c. Patients with extenuating circumstances who present without an ID will be evaluated on an individual basis by the Unit Director or designee to determine whether a controlled substance prescription will be issued. 2. Pick-up procedure: a. Patient or designee presents ID to the designated staff member. b. Designated staff member will verify the ID, collect the recipient s signature, initial the log and issue the prescription. 3. Security of controlled substance prescriptions: a. Controlled substance prescriptions MUST be secured in a locked area at all times. b. Each clinic shall have a defined process for staff to manage access to the locked area. 4. All controlled substance prescriptions that are not given to the patient by clinician will be logged in and out of the locked area using the approved log. Logs are patient specific. All clinics will utilize the approved log to document the following elements: a. prescription written b. prescription signed in. Requires initials of one licensed staff member c. of next appointment with PCP (every 6 months) d. patient may pick up prescription e. Number of prescriptions to release to patient (prescriptions with consecutive start dates) f. Rx paper control number g. Patient name and label h. Drug prescribed (including drug, dose and quantity) i. UDM (Urine Drug Screen) is required at least every 6 months or more frequently as determined by the clinician j. ID verified k. Signature of person picking up prescription l. prescription sign out m. Issuer s initials 5. Any controlled substance prescription not associated with a Controlled Medicine Agreement and not picked up within 7 days of being written must be destroyed by shredding in the presence of two witnesses. Both witnesses must be licensed and sign the accompanying log and attest to the prescription s destruction. 6. Any prescription associated with a Controlled Medicine Agreement and not picked up within 30 days past the fill date must be destroyed by shredding in the presence of two witnesses. Both witnesses must be licensed and sign the accompanying log and attest to the prescription s destruction. Page 4 of 9
5 7. After normal clinic business hours, a lock box will be used by providers to secure controlled substance prescriptions pending issuance. Printed controlled substance prescriptions must not be left unsecured anywhere. MAIL ORDER PROCESS 1. Schedule III, IV, and V controlled substance prescriptions can be mailed to patients via registered mail with signature upon receipt. 2. Schedule II controlled substance prescriptions cannot be mailed. DEFINITIONS Chronic Pain means pain that persists for longer than three consecutive months. This does not include pain associated with a terminal condition. Controlled Substance - a drug or substance listed in Schedules I through V of the Controlled Substances Act or rules adopted. There are five established schedules of controlled substances to be known as Schedules I, II, III, IV and V. Schedule placement is dependent on potential for abuse, medical uses (none, restricted or acceptable), and/or severity of psychological and physical dependence. Benzodiazepines: alprazolam, clobazam, clonazepam, chlorazepate, chlordiazepoxide, diazepam, lorazepam, oxazepam, temazepam Opioids: codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, oxycodone, tramadol Stimulants: Amphetamines (Adderall, Dexedrine, Vyvanse), Methylphenidate (Ritalin, Concerta, Methylin) Any Government issued or other photo ID including but not limited to: Driver s licenses Photo ID issued by the Dept. of Transportation or privately owned affiliates Military photo ID School ID SUMMARY OF CHANGES Added Changes related to BOP Management of pain and other conditions with controlled substances NMAC updated 11/30/16. Added pediatric management with controlled substances. Added Changes related to BOP Control Substance laws NMAC Areas of Responsibility: added prescriber responsibilities, medical director for oversight, urine drug screens every 6 months, PMP review every 6 months. Deleted specialty care record maintenance. Under #4: Removed Brief Pain Index (BPI) requirement. Added BOP definition of chronic pain. Removed requirement to record patient/designee driver s license or ID number. Added mail order process. Added PMP, UDM checked columns and reformatted attachment C: Controlled Substance Prescription Sign-out log Replaces Controlled Substance Prescription Processing Security & Issuance, 8/10/2010. Replaced medication with substance except on patient documents to have language agreement with regulatory bodies. Removed key sign out log and requirements for key sign out. Page 5 of 9
6 RESOURCES/TRAINING Training will occur by clinic Unit Director, RN Supervisors, and Office Supervisors. Ongoing staff training and new hires will be addressed by staff in the orientation process. Attending physicians will train advanced practice providers and resident staff. DOCUMENT APPROVAL & TRACKING Item Contact Approval Owner ED, Primary Care & ED, Specialty Care Louis Achusim, ED Pharmacy, Cynthia Lujan, Ambulatory Pharmacy, Consultant(s) Richard D Angio, Pharm D, BCPS, Director of Clinical Pharmacy, Alisha Parada, FACP, MD Internal Medicine, George Comerci MD Committee(s) Ambulatory Management Council, Medical Executive Committee, UNMH PPG Committee Y Nursing Officer Sheena Ferguson, Chief Nursing Officer Y Medical Officer Associate Dean for Clinical Affairs Y Official Approver Kori Beech, Administrator Ambulatory Services Y Official Signature Kori Beech (on Sharepoint) : 3/20/2018 Effective 3/20/2018 ATTACHMENTS A. Controlled Medicine Prescription Pick-up Designee Form B. Controlled Substance Prescription Sign-out log Page 6 of 9
7 Attachment A CONTROLLED MEDICINE AGREEMENT PRESCRIPTION PICK-UP DESIGNEE FORM I,, hereby identify the following individuals to act as my designee for the purpose of picking up my controlled medicine prescriptions. I understand that I may designate up to 3 people, 18 years of age or older. I also understand and agree that if anyone other than the 3 documented designees comes to the clinic for picking up controlled medicine prescriptions, they will not be given the prescriptions and will be asked to leave the clinic. I may withdraw permission at any time during clinic hours in person. The form will be marked as withdrawn and this person will no longer be allowed to pick-up controlled medicine prescriptions. A new form will be initiated at this time, to ensure accuracy of authorized persons. I agree to follow the terms of the Controlled Medicine Agreement (if applicable) and come into the clinic to pick up my prescriptions when a random urine specimen has been ordered. I also understand that my prescriptions will not be given to the designee when a urine specimen is required. Authorized Persons: Name Relationship Name Relationship Name Patient / Witness Signature: Relationship Patient Signature Witness Signature Patient Sticker Page 7 of 9
8 Attachment C: Controlled Substance RX Sign Out Log Log-in Procedure: 1. Enter date and initials of licensed personnel verifying log in of prescription. 2. Check last UDM, PMP date (due Q6 mo.). 4. Enter drug information. Sign out procedure: 1. Enter date of pick up. 2. Verify ID 3. Obtain signature of person picking up RX. 4. log. Destruction of RX Procedure: 1. Prescriptions should be destroyed if not picked up 30 days after fill date. 2. Enter date in sign out columns & write destroyed in name/sig column. 3. Enter initials of two licensed personnel verifying destruction of RX. Keep last and current year logs in folder Written Log In s UDM Q PCP 6 Months Appoint Circle one and initial when (Q 6mo) completed MAY Pick Up Number of months RX to release RX Control Number Drug (drug, dose & quantity) ID Verified Signature of person picking up RX Signed Out Staff s s Signature s Signature s Signature Page 8 of 9 PATIENT LABEL
9 s Signature s Signature s Signature Effective : 3/23/2017 Page 9 of 9 PATIENT LABEL
April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)
New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Nurse Practitioner Council New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) Peter Ryba, PharmD PMP Director
More informationOCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES
TITLE 16 CHAPTER 10 PART 14 OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES 16.10.14.1 ISSUING AGENCY: New
More informationNew Mexico Board of Pharmacy Prescription Monitoring Program (PMP)
New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) PDMP West Regional Meeting PMP Collaboration with the NM Department of Health April 26, 2018 New Mexico Board of Pharmacy Prescription
More informationLouisiana. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Louisiana Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationPrescription Monitoring Program (PMP)
06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationEffective Date: May 19, Revised Date: August 18, Policy Number: MED Policy 313. Pain Management Long Term Opioid Use
Effective Date: May 19, 2008 Revised Date: August 18, 2015 Approved by: Thomas M Tocher, MD, MPH, Chief Clinical Officer Policy Number: MED Policy 313 Title: Pain Management Long Term Opioid Use POLICY
More informationOklahoma. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationA Bill Regular Session, 2015 SENATE BILL 717
Stricken language would be deleted from and underlined language would be added to present law. 0 State of Arkansas 0th General Assembly As Engrossed: S// H// A Bill Regular Session, SENATE BILL By: Senator
More informationWHAT YOU NEED TO KNOW TO ABOUT AB 474
WHAT YOU NEED TO KNOW TO ABOUT AB 474 PRESENTED BY: NEVADA STATE BOARD OF OSTEOPATHIC MEDICINE 2275 Corporate Circle, Suite 210 Henderson, NV 89074 702-732-2147 Fax 702-732-2079 Web Site: www.bom.nv.gov
More informationLinking Opioid Treatment in Primary Care. Roxanne Lewin M.D.
Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals
More informationVermont. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Vermont Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of
More informationProposed Revision to Med (i)
Proposed Revision to Med 501.02 (i) I. Purpose This rule has been adopted to enable the Board to best protect public health and safety while providing a framework for licensees to effectively treat and
More informationRhode Island. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Rhode Island Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationTennessee. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationPROGRAM FOR THE USE OF CONTROLLED SUBSTANCES OR PRECURSOR/LIST CHEMICALS IN RESEARCH
San Diego State University Environmental Health and Safety PROGRAM FOR THE USE OF CONTROLLED SUBSTANCES OR PRECURSOR/LIST CHEMICALS IN RESEARCH SUMMARY A number of substances or chemicals regulated by
More information4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP
New Mexico s Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy New Mexico and the PMP In 2012, New Mexico had the 3 nd Highest Overdose Death Rate in Nation.! 492 Deaths or a rate of 23.6
More informationVirginia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationOpioid Management of Chronic (Non- Cancer) Pain
Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are
More informationDRUG TESTING FOR DISTRICT PERSONNEL REQUIRED TO HOLD A COMMERCIAL DRIVER S LICENSE
DRUG TESTING FOR DISTRICT PERSONNEL REQUIRED TO HOLD A COMMERCIAL DRIVER S LICENSE School bus drivers and others required to hold a commercial driver s license (CDL) are subject to a drug and alcohol testing
More informationConfirm Limit--Level of detectable drugs in urine to confirm a positive test.
Alcohol and Substance Abuse Policy Purpose To establish and maintain a safe, healthy working environment for all PVFD members; reduce the incidence of accidental injury to members and property; reduce
More informationUser Guide for Transition to the Drug Information System
User Guide for Transition to the Drug Information System Document Revision History Date Description Version Updated By August 12, 2013 New/revised content 1.0 Lori Emery Version 1.0 Page 2 of 13 Table
More informationMandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid
More informationSECTION PRESCRIPTIONS
SECTION.1800 - PRESCRIPTIONS 21 NCAC 46.1801 EXERCISE OF PROFESSIONAL JUDGMENT IN FILLING PRESCRIPTIONS (a) A pharmacist or device and medical equipment dispenser shall have a right to refuse to fill or
More informationGuideline for the Rational Use of Controlled Drugs
Guideline for the Rational Use of Controlled Drugs Ministry of Health Male' Republic of Maldives April 2000 Table of Contents Page Introduction.. 2 1. Procurement and Supply of Controlled Drugs 3 1.1 Import
More informationPART 1306 PRESCRIPTIONS. 21 CFR Ch. II ( Edition)
1305.16 1305.16 Special procedure for filling certain order forms. (a) The purchaser of carfentanil etorphine hydrochloride or diprenorphine shall submit copy 1 and 2 of the order form to the supplier
More informationNew Mexico. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile New Mexico Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationWest Virginia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile West Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationUse of Controlled Substances in Research.
3341-7-09 Use of Controlled Substances in Research. Applicability Faculty and staff who hold federal Drug Enforcement Administration (DEA) licenses to use controlled substances for research purposes. Responsible
More informationSubstance Abuse Policy
Substance Abuse Policy Purpose Dave Loden Construction Inc., henceforth referred to as DLC, values its employees and recognizes their need for a safe and healthy work environment. Employees abusing drugs
More informationPatient Agreement for the use of Opioid Medications
today s date Patient Name date of birth Patient Agreement for the use of Opioid Medications The purpose of this agreement is to give you information about the medications that may be part of your treatment
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Opioid Analgesics Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 11.17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the
More informationMark W. Caverly, Chief Liaison and Policy Section
DEA Issues: An Update Harold Rogers National Prescription Drug Monitoring Meeting Meeting September 24 25, 2009 Mark W. Caverly, Chief Liaison and Policy Section Prescription Drug Abuse Prescription Drug
More informationHUMA RESOURCES POLICY
HUMA RESOURCES POLICY Title: Drug Free Workplace Policy No: 3.08 Originator: Human Resources Page: 1 of 7 Purpose To provide written notification to employees that Children s Medical Center of Dallas (Children
More informationAntidepressants for treatment of depression.
JR3 340 1 of 9 PSYCHOTROPIC MEDICATIONS PURPOSE The use of psychotropic medication as part of a youth's comprehensive mental health treatment plan may be beneficial. The administration of psychotropic
More informationAdministering Medicines to Students Asthma Inhaler Exemption
Administering Medicines to Students Asthma Inhaler Exemption Any school employee authorized in writing by the district administrator or school principal: 1. May assist in the self-administration of any
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this policy
More informationFlorida A & M University Office of Human Resources INTERNAL OPERATING PROCEDURE. Procedure No. HR-7000
Subject: Alcohol and Drug Testing Policy Florida A & M University Office of Human Resources INTERNAL OPERATING PROCEDURE Procedure No. HR-7000 Authority: Florida Statutes 1001.74; Chapter 112.0455, Florida
More informationControlled Substance Prescribing: A Physician s Guide. Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System
Controlled Substance Prescribing: A Physician s Guide Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System Objectives Review schedules of controlled substances and their propensity for
More informationManaging Narcotics on Workers Comp Claims. Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc.
Managing Narcotics on Workers Comp Claims Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc. October 21, 2014 Outline Rationale Scope list drug list Recommended
More informationTechnician Tutorial: Scheduled Drugs
(Page 1 of 8) Technician Tutorial: Scheduled Drugs In the U.S., the federal Controlled Substances Act (CSA) regulates controlled substances. The U.S. Drug Enforcement Administration (DEA), which is a part
More informationPATIENT SIGNATURE: DOB: Date:
CINCINNATI PAIN PHYSICIANS, LLC (CPP) ACKNOWLEDGEMENT OF RECEIPT OF NOTICE OF PRIVACY PRACTICES By signing below, I acknowledge that I have received a copy of CPP s Notice of Privacy Practices. The Notice
More informationIdentification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities
Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities Svetla Slavova, PhD Sara LaMantia, MS Terry Bunn, PhD Tracey Corey, MD 2016 Safe States Annual Meeting April 13, 2016, Albuquerque,
More informationControlled Substances Program. For Academic Units
Brigham Young University Page 1 Provo, Utah Controlled Substances Program For Academic Units Last Revised: November 30, 2009 Brigham Young University Page 2 TABLE OF CONTENTS Section Title Page 1.0 Overview
More informationReadopt with amendment Med 502, effective (Document #11090), to read as follows:
Adopted Rules 11-2-16 1 Readopt with amendment Med 502, effective 5-3-16 (Document #11090), to read as follows: PART Med 502 OPIOID PRESCRIBING Med 502.01 Applicability. This part shall apply to the prescribing
More informationUtah. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Utah Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view
More informationMandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable
Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid
More informationThis Chapter Contains:
This Chapter Contains: State and Federal Laws Relating to Controlled Substances and Other Medications Drugs Used in Animal Shelters Acquiring Controlled Substances Record Keeping of Controlled Substances
More informationClinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19
Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationOpioid Pain Contracts: A Resident Driven Quality Improvement Project
Opioid Pain Contracts: A Resident Driven Quality Improvement Project A Response to the Opioid Epidemic Dr. Phillip Knouse Dr. Victoria Montgomery Disclosure None Objectives Discuss the current Opioid Epidemic
More informationOPIOID PRESCRIBING RULES. May 17, 2017 Webinar
OPIOID PRESCRIBING RULES May 17, 2017 Webinar Outline Introduction and Universal Precautions Dr. Levine, Commissioner, Health Department 15 Minutes Acute Pain Dr. Patti Fisher, UVMMC 20 Minutes Chronic
More informationPRESCRIPTION DRUG MONITORING PROGRAM
PRESCRIPTION DRUG MONITORING PROGRAM ST. LOUIS COUNTY Q2 2017 Contents Executive Summary... 2 User Registration & System Utilization... 4 Dispensation Rates... 6 Dispensation Rates by Geography... 6 Dispensation
More informationChapter 18 Advanced Life Support (ALS) Controlled Substances March 2009
Division 05 Emergency Medical March 2009 POLICY This General Order establishes procedures, as mandated by the Comprehensive Drug Abuse Prevention and Control Act of 1970 (Controlled Substances Act), to
More informationUNIVERSITY POLICY. Revised: Contact:
UNIVERSITY POLICY Policy Name: Policy for Controlled Substances Section #: 90.2.3 Section Title: Compliance Approval Authority: Responsible Executive: Responsible Office: Formerly Book: President Adopted:
More informationClinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18
Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: LA.PPA.12 Effective Date: 02/11 Last Review Date: 01/18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy for
More informationSANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery
Section Sub-section Policy Policy# Pharmacy SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery Pyxis MedStation Controlled Substances 17.102 Page 11 of 5 Programmatic
More informationDispensing and administration of emergency opioid antagonist without a
68-7-23. Dispensing and administration of emergency opioid antagonist without a prescription. (a) A pharmacist may dispense an FDA-approved emergency opioid antagonist and the necessary medical supplies
More informationPractice Direction Refill History Recording System
1.0 Scope and Objective: 1.1 Expected Outcome Practice Direction Refill History Recording System This document is a practice direction by Council concerning implementation of concept of prescription refill
More informationResearch Consent Form Newton-Wellesley Hospital 2014 Washington Street Newton, MA 02462
Protocol Title: Principal Investigator: Description of Subject Population: Protocol Version: Consent Form Revision Date: ABOUT THIS CONSENT FORM STUDY CONTACTS
More information416 DRUG AND ALCOHOL TESTING I. PURPOSE
416 DRUG AND ALCOHOL TESTING I. PURPOSE A. The school board recognizes the significant problems created by drug and alcohol use in society in general, and the public schools in particular. The school board
More informationMonash University Procedure. High Risk Scheduled Drugs and Poisons Procedure (S8/9/11)
Monash University Procedure Procedure Title Parent Policy High Risk Scheduled Drugs and Poisons Procedure (S8/9/11) OHS Policy Date Effective 19 September 2017 Review Date September 2020 Procedure Owner
More informationISSUING AGENCY: Regulation and Licensing Department - NM Board of Osteopathic Medical Examiners.
Code of New Mexico Rules Title 16. Occupational and Professional Licensing Chapter 17. Osteopathic Medicine and Surgery Practitioners Part 5. Prescribing and Distribution of Controlled Substances 16.17.5.
More informationSection I. Short-acting opioid Prior Authorization Criteria
Request for Prior Authorization for Opioid analgesics Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 Requests for opioid analgesics may be subject to prior authorization
More informationPrescription Drug Monitoring Program
California Department of Justice Prescription Drug Monitoring Program May, 2016 Health and Safety Code section 11165. (a) To assist health care practitioners in their efforts to ensure appropriate prescribing,
More informationQUALITY ASSURANCE GUIDELINES FOR LATENT PRINT EXAMINERS
QUALITY ASSURANCE GUIDELINES FOR LATENT PRINT EXAMINERS Preamble SWGFAST recognizes the importance and significance of establishing Quality Assurance protocols and procedures for friction ridge examination.
More informationTemplate Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices
Name of Dental Practice : Objectives To ensure implementation of the regulations and guidance on safe and secure handling of midazolam and other controlled drugs (CDs) Scope To cover all aspects of obtaining
More informationCountable Controlled Substances What are they and why do we need to count them so carefully every day?
Countable Controlled Substances What are they and why do we need to count them so carefully every day? In order to help protect people from the abuse of drugs and other substances, the Federal Government
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 4000-3 Program Opioid Overutilization Cumulative Drug Utilization Review Criteria Medication Includes all salt forms, single and
More informationUpdated: 08/2017 DMMA Approved: 11/2017
Request for Prior Authorization for Therapy to Treat Binge Eating Disorder Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for medications to treat Binge
More informationCLINTON-ESSEX-WARREN-WASHINGTON BOCES Drug and Alcohol Testing. Champlain Valley Educational Services P.O. Box 455 Plattsburgh, NY
CLINTON-ESSEX-WARREN-WASHINGTON BOCES 9095 Drug and Alcohol Testing Champlain Valley Educational Services P.O. Box 455 Plattsburgh, NY 12901-0455 TABLE OF CONTENTS Drug and Alcohol Testing... 3 A. Purpose...
More informationMinnesota. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Minnesota Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationSUBJECT: Effective Date: Policy Number: Controlled Substance and Prescription Drugs 11/30/
Division of Research SUBJECT: Effective Date: Controlled Substance and Prescription Drugs 11/30/2018 Supersedes: Page Of 12/04/2015 04/25/2007 1 6 Responsible Authorities: Vice President, Research Institutional
More informationPRESCRIBING GUIDELINES
Ohio Department of Health RESPONSE TO OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: PRESCRIBING GUIDELINES MIPA CONFERENCE PREVENTING INJURY: FROM RESEARCH TO PRACTICE TO PEOPLE SEPTEMBER 30, 2013 Christy
More informationThe Latest Prescription Trends for Controlled Prescription Drugs
The Latest Prescription Trends for Controlled Prescription Drugs September 1, 2015 Christopher M. Jones PharmD, MPH Senior Advisor Office of Public Health Strategy and Analysis Office of the Commissioner
More informationOur Journey to Addressing the PA PDMP Program. Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System
Our Journey to Addressing the PA PDMP Program Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System 1 Geisinger Health System Geisinger Health System is an integrated
More informationPHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION October 29, 1998
PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION October 29, 1998 Questions 1 20 are multiple choice; please record answers on Side 2 of a Standard Answer Sheet, Form 1158. Follow the instructions
More informationWisconsin Statewide Substance Abuse Prevention Training Wisconsin Dells June 12, 2015
Wisconsin Statewide Substance Abuse Prevention Training Wisconsin Dells June 12, 2015 1 Presenter Andrea Magermans Program Analyst of the Wisconsin PDMP Wisconsin Department of Safety and Professional
More informationCOMPLETE DRUG AND ALCOHOL POLICY & Testing Policy
COMPLETE DRUG AND ALCOHOL POLICY & Testing Policy... Rev 12/2012 1 I. STATEMENT OF POLICY Robért Resources LLC. ( Robért s ) and it s related companies is committed to providing safe, healthful, and efficient
More informationORDINANCE NO AN ORDINANCE ESTABLISHING A POLICY FOR A DRUG-FREE WORKPLACE
ORDINANCE NO. 2003-03 AN ORDINANCE ESTABLISHING A POLICY FOR A DRUG-FREE WORKPLACE BE IT ORDAINED BY THE CITY COUNCIL OF CHEROKEE VILLAGE, ARKANSAS, THAT; SECTION 1. Purpose of Policy The City has a vital
More informationControlled Substances Program Procedures. UC Merced Environmental Health and Safety August 2015
Controlled Substances Program Procedures UC Merced Environmental Health and Safety August 2015 0 I. Introduction II. III. IV. Definitions Registrations Campus Authorization Requirements V. Training VI.
More informationThe Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.
The Wisconsin Prescription Drug Monitoring Program Wisconsin Nurses Association Jail Health Care Conference May 21, 2018 WI PDMP Timeline PDMP Overview January 2013 WI PDMP operational April 2017 WI epdmp
More informationOregon Prescription Drug Monitoring Program
Oregon Prescription Drug Monitoring Program 2013 Annual Report to the PDMP Advisory Commission PUBLIC HEALTH DIVISION Prescription Drug Monitoring Program Oregon Prescription Drug Monitoring Program 2013
More informationTRIM reference DD17/ Endorsed by Publication date Review date
Participant procedure: drug Procedures provide practical step by step guidance to describe processes and actions required to enable the implementation of a policy or guideline. They can also be developed
More informationA resident's salary will continue, during the time they are exercising the Grievance Procedure rights, by requesting and proceeding with a hearing.
GRIEVANCE PROCEDURE GUIDELINES FOR RESIDENTS (WCGME) Residents employed by the Wichita Center for Graduate Medical Education are entitled to participate in the Grievance Procedure in the event an Adverse
More informationAdministration of Medication
Administration of Medication Prescribed medications must arrive in a container with the original, unaltered prescription label attached. The label must display all legal information required for a pharmacist
More informationMedication Agreements Promoting awareness, dialogue and level-set expectations
Medication Agreements Promoting awareness, dialogue and level-set expectations A young man had his leg amputated following a work-related injury. His pain doctor, by all accounts, was trying to responsibly
More informationAPPLICATION FOR ADMISSION (PLEASE PRINT CLEARLY)
1317 w. Washington Blvd. Fort Wayne, In. 46802 260-424-2341 APPLICATION FOR ADMISSION (PLEASE PRINT CLEARLY) NAME: _ FIRST MI LAST DATE OF BIRTH: / / AGE: SOCIAL SECURITY NUMBER: LAST OR CURRENT ADDRESS:
More informationTHE CENTER FOR ADVANCED REPRODUCTIVE SERVICES (CARS) (The Center) CONSENT TO PERFORM THERAPEUTIC DONOR INSEMINATION WITH ANONYMOUS DONOR SPERM
THE CENTER FOR ADVANCED REPRODUCTIVE SERVICES (CARS) (The Center) CONSENT TO PERFORM THERAPEUTIC DONOR INSEMINATION WITH ANONYMOUS DONOR SPERM Partner #1 Last Name (Surname): Partner #1 First Name: Partner
More informationBehavioral Health in PACE: Substance Abuse
Behavioral Health in PACE: Substance Abuse NPA s Quality Symposium 2017 June 9th, 2017 Bharati Srivastava MD MBA FACP AGSF Mercy LIFE Sharon Hill Mercy LIFE Southeastern PA Trinity Health Inc. Objectives
More informationPROFICIENCY TESTING POLICY
Supersedes Prepared by: APPROVALS in this section Approved by: Date: Laboratory Director RECORD OF REVIEWS Date Signature Title Procedural Changes/Review VERSION HISTORY Revision # 0 Section #/Changes
More informationData Integration and Analysis for Improved Drug Overdose Surveillance in Kentucky
Data Integration and Analysis for Improved Drug Overdose Surveillance in Kentucky Svetla Slavova, PhD Terry Bunn, PhD Bureau of Justice Assistance Research-Practitioner Partnership & Data-Driven Pilots
More informationAN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE
AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE Valerie Carrejo, MD Assistant Professor UNM Family Medicine Advances in Primary Care April 14, 2017 Objectives Review the basic
More informationDr. Smith. Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force
Dr. Smith Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force 1 1 How We Got Here 2 The Epidemic 3 4 San Diego Death Diaries
More informationOCCUPATIONAL AND PROFESSIONAL LICENSING OPTOMETRIC PRACTITIONERS CONTINUING EDUCATION
TITLE 16 CHAPTER 16 PART 13 OCCUPATIONAL AND PROFESSIONAL LICENSING OPTOMETRIC PRACTITIONERS CONTINUING EDUCATION 16.16.13.1 ISSUING AGENCY: New Mexico Board of Optometry. [10-14-95; 2-15-99; 16.16.13.1
More informationPRESCRIPTION DRUG MONITORING PROGRAM ST. CHARLES COUNTY Q1 2018
PRESCRIPTION DRUG MONITORING PROGRAM ST. CHARLES COUNTY Q1 2018 Contents Executive Summary... 2 User Registration & System Utilization... 4 Dispensation Rates... 6 Dispensation Rates by Geography... 6
More informationCalifornia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationWEST COAST DISTRICT MUNICIPALITY SUBSTANCE ABUSE POLICY
WEST COAST DISTRICT MUNICIPALITY SUBSTANCE ABUSE POLICY POLICY CONTROL SHEET POLICY TITLE : Substance Abuse Policy POLICY CUSTODIAN : West Coast District Municipality POLICY AUTHOR : H Brand LLF CONSULTATION
More informationHealth & Safety Policy and Procedures Manual SECTION 1 SUBSTANCE ABUSE POLICY
SECTION 1 SUBSTANCE ABUSE POLICY 1. Understanding MEMORANDAM OF UNDERSTANDING Drug and Alcohol Abuse Policy/Program Abuse of alcohol and drugs is recognized as a serious problem in today s workplace that
More informationConroe ADHD Solutions
Diagnosis and Medical Management of ADD/ADHD How do we make the diagnosis of ADD/ADHD? We are very careful to be sure we have the diagnosis correct before considering treatment. In the past there were
More information